Modeling and remodeling of the lung in neonatal chronic lung disease: Implications for therapy

Treatments in Respiratory Medicine

Volumn 4, Issue 5, 2005, Pages 347-359

  Sweet, David G ^a,b   Halliday, Henry L ^a,b  

^a ROYAL MATERNITY HOSPITAL   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA TOCOPHEROL; ANTIINFECTIVE AGENT; ANTIOXIDANT; CYTOKINE; ENDOTOXIN; GELATINASE A; GELATINASE B; GLUCOCORTICOID; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; NITRIC OXIDE; OXYGEN RADICAL; PROTEINASE INHIBITOR; PROTIRELIN; RETINOL; SUPEROXIDE DISMUTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ARTIFICIAL VENTILATION; BLEEDING TIME; BRAIN GROWTH; CARCINOGENIC ACTIVITY; CHRONIC LUNG DISEASE; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; CYTOKINE PRODUCTION; DEGRANULATION; ENZYME RELEASE; EXPERIMENTAL ANIMAL; EXPERIMENTAL RAT; EXTRACELLULAR MATRIX; FETUS LUNG MATURATION; GENETIC CORRELATION; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; INTRAUTERINE INFECTION; LOW DRUG DOSE; LUNG ALVEOLUS CELL; LUNG DEVELOPMENT; LUNG DISEASE; LUNG FIBROSIS; LUNG HYPOPLASIA; LUNG INFECTION; LUNG INJURY; LUNG MODEL; METHEMOGLOBINEMIA; MORBIDITY; MORTALITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MUTAGENIC ACTIVITY; MYELINATION; NEONATAL CHRONIC LUNG DISEASE; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUTROPHIL CHEMOTAXIS; NEWBORN DISEASE; NONHUMAN; OXIDATIVE STRESS; OXYGEN TOXICITY; PERINATAL PERIOD; PNEUMONIA; POSTNATAL CARE; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; RISK ASSESSMENT; SENSORY DYSFUNCTION; SYSTEMIC DISEASE; TISSUE GROWTH; TISSUE REPAIR;

CHRONIC DISEASE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; LUNG; LUNG DISEASES; PROTEASE INHIBITORS; RISK FACTORS;

EID: 31144455397     PISSN: 11763450     EISSN: 11763450     Source Type: Journal    
DOI: 10.2165/00151829-200504050-00006     Document Type: Review

References (149)

1. Burri PH. Structural aspects of prenatal and postnatal development and growth of the lung. In: McDonald JA, editor. Lung growth and development. New York: Marcel Dekker Inc, 1997: 1-35
2. Condon J, Gosden C, Gardener D, et al. Expression of type 2 11 beta-hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. J Clin Endocrinol Metab 1998; 83: 4490-7
3. Muglia LJ, Bae DS, Brown TT, et al. Proliferation and differentiation defects during lung development in corticotropin-releasing hormone-deficient mice. Am J Respir Cell Mol Biol 1999; 20: 181-8
4. Ballard PL. Hormones and lung maturation. Monogr Endocrinol 1986; 28: 197-346
5. Torday JS, Torres E, Rehan VK. The role of fibroblast transdifferentiation in lung epithelial cell proliferation, differentiation, and repair in vitro. Pediatr Pathol Mol Med 2003; 22: 189-207
6. Shan L, Emanuel RL, Dewald D, et al. Bombesin-like peptide receptor gene expression, regulation, and function in fetal murine lung. Am J Physiol Lung Cell Mol Physiol 2004; 286: L165-73
7. Sanchez-Esteban J, Cicchiello LA, Wang Y, et al. Mechanical stretch promotes alveolar epithelial type II cell differentiation. J Appl Physiol 2001; 91: 589-95
8. Bhatt AJ, Amin SB, Chess PR, et al. Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung. Pediatr Res 2000; 47: 606-13
9. Bhatt AJ, Pryhuber GS, Huyck H, et al. Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 164: 1971-80
10. Zeng X, Wert SE, Federici R, et al. VEGF enhances pulmonary vasculogenesis and disrupts lung morphogenesis in vivo. Dev Dyn 1998; 211: 215-27
11. Compernolle V, Brusselmans K, Acker T, et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat Med 2002; 8: 702-10
12. Ross SA, McCaffery PJ, Drager UC, et al. Retinoids in embryonal development. Physiol Rev 2000; 80: 1021-54
13. Massaro D, Massaro GD. Retinoids, alveolus formation, and alveolar deficiency: clinical implications. Am J Respir Cell Mol Biol 2003; 28: 271-4
14. Shaul PW, Afshar S, Gibson LL, et al. Developmental changes in nitric oxide synthase isoform expression and nitric oxide production in fetal baboon lung. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1192-9
15. Savani RC, Cao G, Pooler PM, et al. Differential involvement of the hyaluronan (HA) receptors CD44 and receptor for HA-mediated motility in endothelial cell function and angiogenesis. J Biol Chem 2001; 276: 36770-8
16. Parker RA, Lindstrom DP, Cotton RB. Improved survival accounts for most but not all of the increase in bronchopulmonary dysplasia. Pediatrics 1992; 90: 663-8
17. Northway WH, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline membrane disease. N Engl J Med 1967; 276: 357-68
18. Bonikos DS, Bensch KG, Northway WH, et al. Bronchopulmonary dysplasia: the pulmonary pathologic sequel of necrotising bronchiolitis and pulmonary fibrosis. Hum Pathol 1976; 7: 623-50
19. Jobe AH. The new BPD: an arrest of lung development. Pediatr Res 1999; 46: 641-3
20. Wilson MG, Mikity VG. A new form of respiratory disease in premature infants. Am J Dis Child 1960; 99: 489-99
21. Shennan AT, Dunn MS, Ohlsson A, et al. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988; 82: 527-32
22. Schmidt B, Asztalos EV, Roberts RS, et al. Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms. JAMA 2003; 289: 1124-9
23. Thornton CM, Halliday HL, O'Hara MD. Surfactant replacement therapy in neonates: a comparison of post-mortem pulmonary histology in treated and untreated infants. Pediatr Pathol 1994; 14: 945-53
24. Husain AN, Siddiqui NH, Stocker JT. Pathology of arrested acinar development in postsurfactant bronchopulmonary dysplasia. Hum Path 1998; 29: 710-7
25. Avery ME, Tooley WH, Keller JB, et al. Is chronic lung disease in low birth weight infants preventable? A survey of 8 centers. Pediatrics 1987; 79: 26-30
26. Speer CP. New insights into the pathogenesis of pulmonary inflammation in preterm infants. Biol Neonate 2001; 79: 205-9
27. Philip AGS. Oxygen plus pressure plus time: the etiology of BPD. Pediatrics 1975; 55: 44-50
28. Coalson JJ, Winter VT, Siler-Khodr T, et al. Neonatal chronic lung disease in extremely immature baboons. Am J Respir Crit Care Med 1999; 160: 1333-46
29. Gibson AT. Perinatal corticosteroids and the developing lung. Paediatr Respir Rev 2002; 3: 70-6
30. Jobe AH, Ikegami M. Antenatal infection/inflammation and postnatal lung maturation and injury. Respir Res 2001; 2: 27-32
31. Watterberg KL, Demers LM, Scott SM, et al. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics 1996; 97: 210-5
32. Kotecha S, Wilson L, Wangoo A, et al. Increased IL-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res 1996; 40: 250-6
33. Groneck P, Speer CP. Pulmonary inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr Pulmonol Suppl 1997; 16: 29-30
34. Kraybill EN, Runyan DK, Bose CL, et al. Risk factors for chronic lung disease in infants with birth weights of 751-1000 grams. J Pediatr 1989; 115: 115-20
35. Auten RL, Vozzelli M, Clark RH. Volutrauma: what is it, and how do we avoid it? Clin Perinatol 2001; 28: 505-15
36. Tremblay L, Valenza F, Ribiero SP, et al. Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model. J Clin Invest 1997; 99: 944-52
37. Muscedere JG, Mullen JB, Gan K, et al. Tidal ventilation at low airway pressures can augment lung injury. Am J Respir Crit Care Med 1994; 149: 1327-34
38. Dreyfuss D, Saumon G. Ventilator-induced lung injury: lessons from experimental studies. Am J Respir Crit Care Med 1998; 157: 294-323
39. Bjorklund LJ, Ingimarsson J, Curstedt T, et al. Manual ventilation with a few large breaths at birth compromises the therapeutic effect of subsequent surfactant replacement in immature lambs. Pediatr Res 1997; 42: 348-55
40. Henderson-Smart DJ, Bhuta T, Cools F, et al. Elective high frequency oscillatory ventilation versus conventional ventilation for acute pulmonary dysfunction in preterm infants. Cochrane Database Syst Rev 2003; (1): CD000104
41. Cheema IU, Ahluwalia JS. Feasibility of tidal volume-guided ventilation in newborn infants: a randomized, crossover trial using the volume guarantee modality. Pediatrics 2001; 107: 1323-8
42. Stark AR. High-frequency oscillatory ventilation to prevent bronchopulmonary dysplasia: are we there yet? N Engl J Med 2002; 347: 682-3
43. Frank L, Sosenko IRS. Development of lung antioxidant enzyme system in late gestation: possible implications for the prematurely born infant. J Pediatr 1987; 110: 9-14
44. Saugstad OD. Update on oxygen radical disease in neonatology. Curr Opin Obstet Gynecol 2001; 13: 147-53
45. Coalson JJ, Winter V, deLemos RA. Decreased alveolarization in baboon survivors with bronchopulmonary dysplasia. Am J Respir Crit Care Med 1995; 152: 640-6
46. Han RN, Buch S, Tseu I, et al. Changes in structure, mechanics, and insulin-like growth factor-related gene expression in the lungs of newborn rats exposed to air or 60% oxygen. Pediatr Res 1996; 39: 921-9
47. STOP-ROP: Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP): a randomized, controlled trial. Pediatrics 2000; 105: 295-310
48. Cole CH, Wright KW, Tarnow-Mordi W, et al. Resolving our uncertainty about oxygen therapy. Pediatrics 2003; 112: 1415-9
49. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000; 342: 1500-7
50. Yoon B, Jun J, Romero R, et al. Amniotic fluid inflammatory cytokines (interleukin-6, interleukin-1 beta and tumor necrosis factor-alpha), neonatal brain white matter lesions and cerebral palsy. Am J Obstet Gynecol 1997; 177: 19-26
51. Schmidt B, Cao L, Mackensen-Haen S, et al. Chorioamnionitis and inflammation of the fetal lung. Am J Obstet Gynecol 2001; 185: 173-7
52. Yoon BH, Romero R, Jun JK, et al. Amniotic fluid cytokines (interleukin-6, tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8) and the risk for the development of bronchopulmonary dysplasia. Am J Obstet Gynecol 1997; 177: 825-30
53. Curley AE, Sweet DG, Thornton CM, et al. Chorioamnionitis and increased neonatal lung lavage fluid matrix metalloproteinase-9 levels: implications for antenatal origins of chronic lung disease. Am J Obstet Gynecol 2003; 188: 871-5
54. Curley AE, Sweet DG, MacMahon KJ, et al. Chorioamnionitis increases matrix metalloproteinase-8 levels in bronchoalveolar lavage fluid from preterm babies. Arch Dis Child Fetal Neonatal Ed 2004; 89: F61-4
55. Murphy G, Docherty AJP. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992; 7: 120-5
56. Peppin GJ, Weiss SJ. Activation of the endogenous metalloproteinase, gelatinase, by triggered human neutrophils. Proc Natl Acad Sci U S A 1986; 83: 432-6
57. Stockley RA. Neutrophils and protease/ antiprotease imbalance. Am J Respir Crit Care Med 1999; 160: S49-52
58. Mackarel JA, Cottell DC, Russell KJ, et al. Migration of neutrophils across human pulmonary endothelial cells is not blocked by matrix metalloproteinase or serine protease inhibitors. Am J Respir Cell Mol Biol 1999; 20: 1209-19
59. O'Connor CM, Fitzgerald MX. Matrix metalloproteases and lung disease. Thorax 1994; 49: 602-9
60. Sweet DG, Curley AE, MacMahon K, et al. Type-I collagenases in bronchoalveolar lavage fluid from preterm babies at risk of developing chronic lung disease. Arch Dis Child Fetal Neonatal Ed 2001; 84: F168-71
61. Danan C, Jarreau PH, Franco ML, et al. Gelatinase activities in the airways of premature infants and development of bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1086-93
62. Davidson JM. Biochemistry and turnover of lung interstitium. Eur Respir J 1990; 3: 1048-68
63. Minoo P, Penn R, deLemos DM, et al. Tissue inhibitor of metalloproteinase-1 mRNA is specifically induced in lung tissue after birth. Pediatr Res 1993; 34: 729-34
64. Sweet DG, Huggett MT, Moss TJ, et al. Increased lung collagenase levels in a sheep model of chorioamnionitis: implications for the development of neonatal chronic lung disease [abstract no. 2765]. Pediatr Res 2002; 51 Suppl. 2: 474A
65. Sweet DG, Pizzotti J, Wilbourn M, et al. Matrix metalloproteinase-9 in the airways of infants at risk of developing chronic lung disease [abstract]. Eur Respir J 1999; 14 Suppl. 30: 248s
66. Willet KE, Jobe AH, Ikegami M, et al. Pulmonary interstitial emphysema 24 hours after antenatal betamethasone treatment in preterm sheep. Am J Respir Crit Care Med 2000; 162: 1087-94
67. Speer CP, Ruess D, Harms K, et al. Neutrophil elastase and acute pulmonary damage in neonates with severe respiratory distress syndrome. Pediatrics 1993; 91: 794-9
68. Ohki Y, Kato M, Kimura H, et al. Elevated type IV collagen in bronchoalveolar lavage fluid from infants with bronchopulmonary dysplasia. Biol Neonate 2001; 79: 34-8
69. Pardo A, Selman M, Ridge K, et al. Increased expression of gelatinases and collagenase in rat lungs exposed to 100% oxygen. Am J Respir Crit Care Med 1996; 154: 1067-75
70. Frears ER, Zhang Z, Blake DR, et al. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 1996; 381: 21-4
71. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem 1997; 378: 151-60
72. Schock BC, Sweet DG, Ennis M, et al. Oxidative stress and increased type-IV collagenase levels in bronchoalveolar lavage fluid from newborn babies. Pediatr Res 2001; 50: 29-33
73. Crowley P. Prophylactic corticosteroids for preterm birth. Cochrane Database Syst Rev 2003; (1): CD000065
74. Ballard PL, Ning Y, Polk D, et al. Glucocorticoid regulation of surfactant components in immature lambs. Am J Physiol 1997; 17: L1408-57
75. Keeney SE, Mathews MJ, Rassin DK. Antioxidant enzyme responses to hyperoxia in preterm and term rats after prenatal dexamethasone administration. Pediatr Res 1993; 33: 177-80
76. Asoh K, Kumai T, Murano K, et al. Effect of antenatal dexamethasone treatment on Ca2+-dependent nitric oxide synthase activity in rat lung. Pediatr Res 2000; 48: 91-5
77. Willet KE, McMenamin P, Pinkerton KE, et al. Lung morphometry and collagen and elastin content: changes during normal development and after prenatal hormone exposure in sheep. Pediatr Res 1999; 45: 615-25
78. Willet KE, Jobe AH, Ikegami M, et al. Lung morphometry after repetitive antenatal glucocorticoid treatment in preterm sheep. Am J Respir Crit Care Med 2001; 163: 1437-43
79. Pillow JJ, Hall GL, Willet KE, et al. Effects of gestation and antenatal steroid on airway and tissue mechanics in newborn lambs. Am J Respir Crit Care Med 2001; 163: 1158-63
80. Adamson IY, King GM. Postnatal development of rat lung following retarded fetal lung growth. Pediatr Pulmonol 1988; 4: 230-6
81. Pierce RA, Mariencheck WI, Sandefur S, et al. Glucocorticoids upregulate tropoe-lastin expression during late stages of fetal lung development. Am J Physiol 1995; 268: L491-500
82. Newnham JP, Moss TJ, Padbury JF, et al. The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep. Am J Obstet Gynecol 2001; 185: 190-7
83. Kallapur SG, Kramer BW, Moss TJ, et al. Maternal glucocorticoids increase endotoxin induced lung inflammation in preterm lambs. Am J Physiol Lung Cell Mol Physiol 2003; 284: L633-42
84. Doyle LW, Ford GW, Rickards AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. Pediatrics 2000; 106 (1): E2
85. Guinn DA, Atkinson MW, Sullivan L, et al. Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: a randomized controlled trial. JAMA 2001; 286: 1581-7
86. Aghajafari F, Murphy K, Ohlsson A, et al. Multiple versus single courses of antenatal corticosteroids for preterm birth: a pilot study. J Obstet Gynaecol Can 2002; 24: 321-9
87. McEvoy C, Bowling S, Williamson K, et al. The effect of a single remote course versus weekly courses of antenatal corticosteroids on functional residual capacity in preterm infants: a randomized trial. Pediatrics 2002; 110: 280-4
88. Crowther CA, Harding J. Repeat doses of prenatal corticosteroids for women at risk of preterm birth for preventing neonatal respiratory disease. Cochrane Database Syst Rev 2003; (3): CD003935
89. Vermillion ST, Soper DE, Newman RB. Neonatal sepsis and death after multiple courses of antenatal betamethasone therapy. Am J Obstet Gynecol 2000; 183: 810-4
90. Banks BA, Cnaan A, Morgan MA, et al. Multiple courses of antenatal corticosteroids and outcome of premature neonates. North American Thyrotropin-Releasing Hormone Study Group. Am J Obstet Gynecol 1999; 181: 709-17
91. Caughey AB, Parer JT. Recommendations for repeat courses of antenatal corticosteroids: a decision analysis. Am J Obstet Gynecol 2002; 186: 1221-9
92. Schellenberg JC, Liggins GC, Manzai M, et al. Synergistic hormonal effects on lung maturation in fetal sheep. J Appl Physiol 1988; 65: 94-100
93. Boshier DP, Holloway H, Liggins GC, et al. Morphometric analyses of the effects of thyrotrophin releasing hormone and cortisol on the lungs of fetal sheep. J Dev Physiol 1989; 12: 49-54
94. Ballard RA, Ballard PL, Creasy R, et al. Respiratory disease in very low birth weight infants after prenatal thyrotropin releasing hormone and glucocorticoid. Lancet 1992; 339: 510-5
95. Knight DB, Liggins GC, Wealthall SR. A randomized, controlled trial of antepartum thyrotropin releasing hormone and betamethasone in the prevention of respiratory distress in preterm infants. Am J Obstet Gynecol 1994; 171: 11-6
96. Australian collaborative trial of antenatal thyrotropin releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease. Lancet 1995; 345: 877-82
97. Ballard RA, Ballard PL, Cnaan A, et al. Antenatal thyrotropin-releasing hormone to prevent lung disease in preterm infants. N Engl J Med 1998; 338: 493-8
98. Crowther CA, Hiller JE, Haslam RR, et al. Australian collaborative trial of antenatal thyrotropin releasing hormone: adverse effects at 12 month follow up. ACTOBAT Study Group. Pediatrics 1997; 99: 311-7
99. Jobe AH, Newnham JP, Willet KE, et al. Effects of antenatal glucocorticoids and endotoxin on the lungs of preterm lambs. Am J Obstet Gynecol 2000, 8
100. Jobe AH, Newnham JP, Willet KE, et al. Endotoxin-induced lung maturation in preterm lambs is not mediated by cortisol. Am J Respir Crit Care Med 2000; 162: 1656-61
101. Newnham JP, Moss TJ, Padbury JF, et al. The interactive effects of endotoxin with prenatal glucocorticoids on short term lung function in sheep. Am J Obstet Gynecol 2001; 185: 190-7
102. Moss T, Nitsos MI, Kramer BW, et al. Intra-amniotic endotoxin induces lung maturation by direct effects on the developing respiratory tract in preterm sheep. Am J Obstet Gynecol 2002; 187: 1059-65
103. Cassell GH, Waites KB, Crouse DT, et al. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet 1988; II: 240-5
104. Pacifico L, Panero A, Roggini M, et al. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997; 16: 579-86
105. Lyon AJ, McColm J, Middlemist L, et al. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998; 78: F10-4
106. Pearson E, Bose C, Snidow T, et al. Trial of vitamin A supplementation in very low birth weight infants at risk for bronchopulmonary dysplasia. J Pediatr 1992; 121: 420-7
107. Watts JL, Milner R, Zipursky A, et al. Failure of supplementation with vitamin E to prevent bronchopulmonary dysplasia in infants less than 1500g birth weight. Eur Respir J 1991; 4: 803-6
108. Davis JM, Rosenfeld WN, Richter SE, et al. Safety and pharmacokinetics of multiple doses of recombinant human CuZn superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics 1997; 100: 24-30
109. Tyson JE, Wright LL, Oh W, et al. Vitamin A supplementation for extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 1999; 340: 1962-8
110. Darlow BA, Graham PJ. Vitamin A supplementation for preventing morbidity and mortality in very low birthweight infants. Cochrane Database Syst Rev 2003; (1): CD000501
111. Massaro GD, Massaro D. Postnatal treatment with retinoic acid increases the number of pulmonary alveoli in rats. Am J Physiol 1996; 270: L305-10
112. Davis JM, Rosenfeld WN, Sanders RJ, et al. Prophylactic effects of recombinant human superoxide dismutase in neonatal lung injury. J Appl Physiol 1993; 74: 2234-41
113. Suresh GK, Davis JM, Soll RF. Superoxide dismutase for preventing chronic lung disease in mechanically ventilated preterm infants. Cochrane Database Syst Rev 2003; (1): CD001968
114. Jankov RP, Negus A, Tanswell AK. Antioxidants as therapy in the newborn: some words of caution. Pediatr Res 2001; 50: 681-7
115. Finer NN, Barrington KJ. Nitric oxide in respiratory failure in the newborn infant. Semin Perinatol 1997; 21: 426-40
116. Kinsella JP, Parker TA, Galan H, et al. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr Res 1997; 41: 457-63
117. Roberts Jr JD, Chiche JD, Weimann J, et al. Nitric oxide inhalation decreases pulmonary artery remodeling in the injured lungs of rat pups. Circ Res 2000; 87: 140-5
118. Schreiber MD, Gin-Mestan K, Marks JD, et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 2003; 349: 2099-107
119. Hogman M, Frostell C, Arnberg H, et al. Bleeding time prolongation and nitric oxide inhalation. Lancet 1993; 341: 1664-5
120. Hallman M, Waffarn F, Bry K, et al. Surfactant dysfunction after inhalation of nitric oxide. J Appl Physiol 1996; 80: 2026-34
121. Robbins CG, Davis JM, Merritt TA, et al. Combined effects of nitric oxide and hyperoxia on surfactant function and pulmonary inflammation. Am J Physiol 1995; 269: L545-50
122. Barrington KJ, Finer NN. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst Rev 2003; (1): CD000509
123. Martin RJ. Nitric oxide for preemies: not so fast. N Engl J Med 2003; 349: 2157-9
124. Baden M, Bauer C, Colle E, et al. Plasma corticosteroids in infants with the respiratory distress syndrome. Pediatrics 1973; 52: 782-7
125. Watterberg KL, Scott SM. Evidence of early adrenal insufficiency in babies who develop bronchopulmonary dysplasia. Pediatrics 1995; 95: 120-5
126. Wang JY, Yeh TF, Lin YJ, et al. Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatr Pulmonol 1997; 23: 193-7
127. Ng PC. The effectiveness and side-effects of dexamethasone in preterm infants with bronchopulmonary dysplasia. Arch Dis Child 1993; 68: 330-6
128. Halliday HL, Ehrenkranz RA, Doyle LW. Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001146
129. Halliday HL, Ehrenkranz RA, Doyle LW. Moderately early (7-14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001144
130. Halliday HL, Ehrenkranz RA, Doyle LW. Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants. Cochrane Database Syst Rev 2003; (1): CD001145
131. Sahebjami H, Domino M. Effects of postnatal dexamethasone treatment on development of alveoli in adult rats. Exp Lung Res 1989; 15: 961-73
132. Blanco LN, Frank L. The formation of alveoli in rat lung during the third and fourth postnatal weeks: effect of hyperoxia, dexamethasone, and desferoxamine. Pediatr Res 1993; 34: 334-40
133. Schwyter M, Burri PH, Tschanz SA. Geometric properties of the lung parenchyma after postnatal glucocorticoid treatment in rats. Biol Neonate 2003; 83: 57-64
134. Gibson AT, Pearse RG, Wales JK. Growth retardation after dexamethasone administration: assessment by knemometry. Arch Dis Child 1993; 69: 505-9
135. Howard E, Benjamins JA. DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during development. Brain Res 1975; 92: 73-87
136. Gramsbergen A, Mulder EJH. The influence of betamethasone and dexamethasone on motor development in young rats. Pediatr Res 1998; 44: 105-10
137. Noble-Jameison CM, Reger R, Silverman M. Dexamethasone in neonatal chronic lung disease: pulmonary effects and intracranial complications. Eur J Pediatr 1989; 148: 365-7
138. Yeh TF, Lin YJ, Huang CC, et al. Early dexamethasone therapy in preterm infants: a follow-up study. Pediatrics 1998; 101: E7
139. O'Shea TM, Kothadia JM, Klinepeter KL, et al. Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics 1999; 104: 15-21
140. Shinwell ES, Karplus M, Reich D, et al. Early postnatal dexamethasone treatment and increased incidence of cerebral palsy. Arch Dis Child Fetal Neonatal Ed 2000; 83: F177-81
141. Shinwell ES. Current dilemmas in postnatal steroid therapy for chronic lung disease in preterm infants. Biol Neonate 2003; 84: 96-100
142. Halliday HL. Guidelines on neonatal steroids. Prenat Neonatal Med 2001; 6: 371-3
143. American Academy of Pediatrics Committee on Fetus and Newborn. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants. Pediatrics 2002; 109: 330-8
144. Halliday HL. Clinical trials of postnatal corticosteroids: inhaled and systemic. Biol Neonate 1999; 76 Suppl. 1: 29-40
145. Shah V, Ohlsson A, Halliday HL, et al. Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev 2003; (1): CD001969
146. Lister P, Iles R, Shaw B, et al. Inhaled steroids for neonatal chronic lung disease. Cochrane Database Syst Rev 2003; (1): CD002311
147. Stiskal JA, Dunn MS, Shennan AT, et al. Alpha-1 proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial. Pediatrics 1998; 101: 89-94
148. Corbel M, Caulet-Maugendre S, Germain N, et al. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J Pathol 2001; 193: 538-45
149. Trifilieff A, Walker C, Keller T, et al. Pharmacological profile of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in models of airway inflammation. Br J Pharmacol 2000; 135: 1655-64